Advancements in Huntington's Disease Treatment

Neurocrine Biosciences reports positive Phase III data for Ingrezza, its drug for Huntington's disease, showcasing its ability to improve chorea in patients. Sage Therapeutics receives FDA Orphan Drug Designation for SAGE-718, a potential oral therapy for cognitive disorders in Huntington's disease. Roche partners with Ionis Pharmaceuticals to develop RNA-targeting programs for Alzheimer's and Huntington's diseases, leveraging Roche's strengths in nervous system disorders. FDA approves Neurocrine Biosciences' Ingrezza for chorea in Huntington's disease, potentially competing with Teva Pharmaceutical's Austedo.